|
Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines |
Medicines for Europe |
05 Nov 2020 |
Health & Consumers |
|
Fulfilling the Biosimilar Promise: Report Highlights Key Principles in Support of a Sustainable Market |
Medicines for Europe |
19 Sep 2016 |
Health & Consumers |
|
Generic & biosimilar medicines pivotal for safe, effective and affordable access to medicines in Europe |
Medicines for Europe |
28 Nov 2019 |
Health & Consumers |
|
Health at a Glance Report highlights public value of generic, biosimilar and value added medicines |
Medicines for Europe |
26 Nov 2018 |
Health & Consumers |
|
IGBA congratulates the Australian Government for maintaining their Biologics Naming Convention and for strengthening pharmacovigilance |
Medicines for Europe |
29 Jan 2018 |
Health & Consumers |
|
IGBA launches a Biosimilar Medicines Information Campaign |
Medicines for Europe |
01 Feb 2018 |
Health & Consumers |
|
Immediately calls on new President of EU Commission to prioritise Healthcare |
Medicines for Europe |
25 Sep 2019 |
Health & Consumers, InfoSociety |
|
IQVIA Institute Scorecards show biosimilar medicines offer win for patients, policymakers and healthcare systems across Europe |
Medicines for Europe |
30 Jun 2020 |
Health & Consumers |
|
Latest Data Shows the Need to Promote Biosimilar and Value Added Medicines for Better Health |
Medicines for Europe |
16 Jun 2017 |
Health & Consumers |
|
Medicines for Europe announces new President, launches Access to Medicines campaign |
Medicines for Europe |
10 Oct 2017 |
Health & Consumers |
|
Medicines for Europe calls for greater cooperation on value added medicines to improve patient-centric innovation |
Medicines for Europe |
22 Nov 2017 |
Health & Consumers |
|
Medicines for Europe can contribute much more to improve healthcare sustainability than described in the OECD “Health at a Glance 2016” report |
Medicines for Europe |
24 Nov 2016 |
Health & Consumers |
|
Medicines for Europe members publish disclosure of Transfers of Value to the healthcare community |
Medicines for Europe |
22 Jun 2018 |
Health & Consumers |
|
Medicines for Europe statement on COVID-19 (‘coronavirus’) |
Medicines for Europe |
13 Mar 2020 |
Health & Consumers |
|
Medicines for Europe to join the ISPOR Issue Panel on value added medicines |
Medicines for Europe |
05 Oct 2017 |
Health & Consumers |
|
Medicines for Europe welcomes Competitiveness Council discussion to stop delocalisation of medicine manufacturing. It is time to effectively position Europe as a global hub for the production of medicines. |
Medicines for Europe |
30 Nov 2018 |
Health & Consumers |
|
Medicines for Europe, APOGEN and Fresenius Kabi hold Open Industry Day in Portugal |
Medicines for Europe |
14 Nov 2019 |
Health & Consumers |
|
New safeguards for patient safety as Falsified Medicines Directive comes into force |
Medicines for Europe |
11 Feb 2019 |
Health & Consumers |
|
Now or never: pragmatism & ambition needed in EU pharma strategy to deliver on Europe’s medicines manufacturing |
Medicines for Europe |
07 Oct 2020 |
Health & Consumers |
|
Oncology, the new era for biosimilar medicines |
Medicines for Europe |
08 Sep 2017 |
Health & Consumers |
|
Parliament’s Health Committee (ENVI) introduces constructive amendments to SPC Manufacturing waiver vote in its official opinion to the Parliament’s Legal Committee (JURI). |
Medicines for Europe |
28 Nov 2018 |
Health & Consumers |
|
Parliament’s Trade Committee votes for jobs and access to medicines with a comprehensive SPC Manufacturing Waiver! |
Medicines for Europe |
04 Dec 2018 |
Health & Consumers |
|
Protecting health: Active generic and biosimilar policies central to EU pharmaceutical strategy |
Medicines for Europe |
03 Mar 2020 |
Health & Consumers |
|
Ready to drive access to medicines |
Medicines for Europe |
24 Jul 2019 |
Health & Consumers |
|
Report identifies 9 key ingredients to improve access to medicines in the hospital setting |
Medicines for Europe |
08 Oct 2019 |
Health & Consumers |
|
Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come |
Medicines for Europe |
18 Jan 2018 |
Health & Consumers, InfoSociety |
|
Risk that European Council will “neuter” SPC manufacturing waiver and give foreign (non-EU) manufacturers strong advantage over EU-based manufacturers |
Medicines for Europe |
12 Oct 2018 |
Health & Consumers |
|
Smart Pharmacovigilance Essential for Patient Safety |
Medicines for Europe |
29 Jan 2020 |
Health & Consumers |
|
SPC manufacturing waiver cannot be derailed by foreign vested interests |
Medicines for Europe |
07 Feb 2019 |
Health & Consumers |
|
SPC manufacturing waiver moves a step closer as influential European Parliament ENVI Committee supports reform |
Medicines for Europe |
18 Sep 2018 |
Health & Consumers |
